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Background: Breast cancer (BC), a heterogeneous disease comprises
different tumour subtypes associated with varied clinical characteristics.
Prognostic factors including age, tumour size, histological subtype and
grade, lymph node status and the expression of estrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth factor receptor
2 (HER2) currently assist routine clinical management. The role of the
androgen receptor (AR) and Vitamin D receptor (VDR) in breast carci-
nomas has drawn great attention in recent years. Breast cancer has long
been associated with vitamin D receptor downregulation. This study eval-
uates the potential correlations of AR and VDR with BC and possible role
as predictors response to neo adjuvant chemotherapy.
Methodology: Between June 2011 and Jan 2013, 116 breast cancer pa-
tients were enrolled. Tissue sections were immunostained for ER, PR,
Her2 Neu, AR and VDR with immunoreactive (IRS) scoring. Patients
with fibroadenoma (n¼30) served as controls for VDR receptor status.
The age of the patients ranged between 32 and 70 years. n¼72 patients
were subjected to neoadjuvant taxane and/or anthracycline based chemo-
therapy according to standard treatment guidelines. Clinical response
was evaluated using WHO criteria.
Results: 31.5% of cases belonged to young age group (<40 years) with
48.0% of the patients were premenopausal; most common stage at presen-
tation was Stage III (62.9%).
69.8% BC patients showed absent VDR expression. Among the VDR
positive group, only 24.6% had high IRS (mean IRS score¼ 2.44+/-3.08)
in contrast to all fibroadenoma patients who were VDR + with 93.3% hav-
ing high IRS scores (mean IRS score of ¼ 6.41+/-1.54) (p¼0.001). In
particular, AR expression was commonly observed in luminal A 21/27
(77.8%) and B 19/30 (63.3%) cancers, but was less frequently seen in hor-
monal negative tumors 25/59 (42.4%). Despite being defined by the
absence of ER and PR expression and being considered hormonally unre-
sponsive, 16/29 (55.1%) Her2 Neu enriched and 9/30 (30%) of TNBC ex-
pressed AR.
In patients offered NAC (n¼72), response grading was done with ma-
jority of patients showing partial response (PR) (65.3%) and 12/72 (16.7%)
patients having complete response (CR). Seven patients with progressive
disease (PD) and 6 with stable disease (SD) who were non-responders,
were offered different chemotherapy regimens. Complete response after
NAC was significantly greater in VDR positive cases (76.92%) and further
greater in high IRS group (100%). AR expression was higher in responders
(55.3% in PR group and 50.0% in CR group) as compared to non-re-
sponders (16.7% in SD group and 28.7% in PD group).
Conclusion: Better response to NAC was seen in AR and/or VDR pos-
itive breast carcinomas compared to negative cases indicating a possibly
increased chemotherapy response. As both receptors are confirmed as bio-
logically relevant, it is possible that hormonal manipulations targeting
them could be useful in treatment but large sample size is needed to deduce
the final statement.
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Background: The application of minimally invasive ablative tech-
niques such as radiofrequency ablation (RFA), high intensity focused ultra-
sound (HIFU) ablation; cryo-ablation, laser-ablation and microwave-
ablation in the treatment for breast cancer are an emerging area of exper-
tise. We performed the first systematic review to evaluate the impact of
these minimal invasive techniques upon objective outcome measures of
breast cancer treatment.
Material and Methods: All studies published up to January 2014 that
evaluated the role of ablative techniques in the treatment of breast cancers
were identified using Medline/Pubmed, EMBASE and Cochrane library
databases. Studies were considered suitable if they were performed on pa-
tients with breast cancers, objectively recorded imaging, histopathological
outcomes and treatment times of the techniques.
Results: We identified 11 studies (10 cohort and 1 randomized control
trial) involving 454 patients, which fulfilled our inclusion criteria. It was
demonstrated that in terms of complete necrosis, staining with haematox-
ylin and eosin (H&E) reported the highest percentage of complete ablation
for HIFU (100%) and RFA (94%) and staining with nicotinamide adenine
dinucleotide (NADH) reported the highest percentages for RFA, cryo-abla-
tion (both 95%) and laser-ablation (100%). Magnetic resonance imaging
(MRI) was successful in demonstrating a decrease in post-treatment
enhancement (pathognomonic of coagulative necrosis) and ultrasound im-
aging was able to accurately demonstrate the absence of residual tumour.
Recorded complications included superficial skin burns in 10 patients (6%)
and local pain in 24 patients (14%). HIFU and microwave-ablation re-
ported the longest treatment time compared to other modalities.
Conclusion: Minimally invasive ablative techniques are able to suc-
cessfully induce coagulative necrosis with a minimal side-effect profile
and reliable follow-up imaging modalities. These minimally invasive tech-
nologies are promising but require assessment in prospectively conducted
trials compared to the current surgical standard to validate their efficacy.
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Background: Because of its diffuse growth pattern, breast invasive
lobular carcinomas (ILC), compared to other invasive breast cancer sub-
types, are more prone to: 1) misleading tumor size in mammography
and ultrasound (MU); 2) multifocality, multicentricity and synchronous bi-
laterality. Although magnetic resonance imaging (MRI) doesn’t bring any
advantage in the management of other breast cancer subtypes, it is still
indicated in ILC. Our aim was to determine the influence of MRI on breast
ILC characterization and surgical outcomes.
Methods: This is a retrospective study of 70 consecutive women diag-
nosed with ILC (confirmed with histology and lack of E-cadherin expres-
sion) at a single institution, between 1/Jan/2007 and 31/Mar/2014. All
underwent MRI, along with clinical examination and MU, and all under-
went primary surgery. We evaluated the correlation between MRI and
size of the tumor on final pathology, presence of occult lesions and change
in surgical management.
Results: Twenty-six conservative surgeries and 44 mastectomies were
performed. MRI overestimated tumor size by> 0.5 cm in 20.6% of tu-
mors and understimated tumor size by > 0.5 cm in 29.4%. MRI per-
formed better than MU to correlate with tumor size in final pathology
(R¼0,748 Vs R¼0,710; p¼0.001). MRI showed 3/70(4,3%) occult lesions
in the contralateral breast. Analysing only women that were initially pro-
posed to conservative surgery (n¼53), we defined three groups, after
MRI: 1) 7(13,2%) patients in which MRI did not differ from MU; 2)
